EA019064B1 - Способы лечения рака с применением хинаксолинового ингибитора pi3k-альфа - Google Patents

Info

Publication number

EA019064B1

EA019064B1 EA200970935A EA200970935A EA019064B1 EA 019064 B1 EA019064 B1 EA 019064B1 EA 200970935 A EA200970935 A EA 200970935A EA 200970935 A EA200970935 A EA 200970935A EA 019064 B1 EA019064 B1 EA 019064B1

Authority

EA

Eurasian Patent Office

Prior art keywords

amino

phenyl

quinoxaline

sulfonyl

methoxy

Prior art date

2007-04-11

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003112 inhibitor Substances 0.000 title claims abstract description 55
• 238000000034 method Methods 0.000 title claims abstract description 47
• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 45
• 201000011510 cancer Diseases 0.000 title claims abstract description 40
• 230000002401 inhibitory effect Effects 0.000 title description 4
• 150000001875 compounds Chemical class 0.000 claims abstract description 102
• 150000003839 salts Chemical class 0.000 claims abstract description 63
• 239000002246 antineoplastic agent Substances 0.000 claims abstract description 38
• 229940127089 cytotoxic agent Drugs 0.000 claims abstract description 36
• 239000012453 solvate Substances 0.000 claims abstract description 32
• 238000011282 treatment Methods 0.000 claims abstract description 22
• 229940100198 alkylating agent Drugs 0.000 claims abstract description 8
• 239000002168 alkylating agent Substances 0.000 claims abstract description 8
• 238000009169 immunotherapy Methods 0.000 claims abstract description 6
• 229940036571 iodine therapy Drugs 0.000 claims abstract description 6
• 230000002285 radioactive effect Effects 0.000 claims abstract description 6
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 22
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 20
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 14
• 229960002930 sirolimus Drugs 0.000 claims description 14
• 229930012538 Paclitaxel Natural products 0.000 claims description 12
• 229960001592 paclitaxel Drugs 0.000 claims description 12
• 229910052697 platinum Inorganic materials 0.000 claims description 11
• 206010060862 Prostate cancer Diseases 0.000 claims description 10
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 10
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 9
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 9
• 206010006187 Breast cancer Diseases 0.000 claims description 8
• 208000026310 Breast neoplasm Diseases 0.000 claims description 8
• 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 8
• 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 8
• 229940123237 Taxane Drugs 0.000 claims description 7
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical group [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims description 7
• 229960004562 carboplatin Drugs 0.000 claims description 7
• 229960001433 erlotinib Drugs 0.000 claims description 7
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 7
• 229940126062 Compound A Drugs 0.000 claims description 6
• NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 6
• 208000005017 glioblastoma Diseases 0.000 claims description 6
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
• 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 5
• 206010009944 Colon cancer Diseases 0.000 claims description 5
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 5
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
• 206010014733 Endometrial cancer Diseases 0.000 claims description 4
• 206010014759 Endometrial neoplasm Diseases 0.000 claims description 4
• 206010033128 Ovarian cancer Diseases 0.000 claims description 4
• 208000029742 colonic neoplasm Diseases 0.000 claims description 4
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 4
• 201000001441 melanoma Diseases 0.000 claims description 4
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
• 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
• 206010041067 Small cell lung cancer Diseases 0.000 claims description 3
• 208000024770 Thyroid neoplasm Diseases 0.000 claims description 3
• 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
• 201000010881 cervical cancer Diseases 0.000 claims description 3
• 208000000587 small cell lung carcinoma Diseases 0.000 claims description 3
• 201000002510 thyroid cancer Diseases 0.000 claims description 3
• 206010007279 Carcinoid tumour of the gastrointestinal tract Diseases 0.000 claims description 2
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 2
• 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
• 208000033781 Thyroid carcinoma Diseases 0.000 claims description 2
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
• 210000004072 lung Anatomy 0.000 claims description 2
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
• 201000002528 pancreatic cancer Diseases 0.000 claims description 2
• 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
• 208000000649 small cell carcinoma Diseases 0.000 claims description 2
• 208000013077 thyroid gland carcinoma Diseases 0.000 claims description 2
• 125000002456 taxol group Chemical group 0.000 claims 2
• 229940068196 placebo Drugs 0.000 claims 1
• 239000000902 placebo Substances 0.000 claims 1
• 201000001514 prostate carcinoma Diseases 0.000 claims 1
• 238000001794 hormone therapy Methods 0.000 abstract description 5
• 229940121647 egfr inhibitor Drugs 0.000 abstract 1
• -1 phosphatidylinositol triphosphate Chemical class 0.000 description 1469
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 657
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 530
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 458
• 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 371
• GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 313
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 243
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 132
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 132
• 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 131
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 121
• 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 98
• DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 95
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 91
• 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 88
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 85
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 85
• BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 74
• YIKSCQDJHCMVMK-UHFFFAOYSA-N Oxamide Chemical compound NC(=O)C(N)=O YIKSCQDJHCMVMK-UHFFFAOYSA-N 0.000 description 72
• 125000000217 alkyl group Chemical group 0.000 description 65
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 62
• 239000004202 carbamide Substances 0.000 description 62
• 229910052739 hydrogen Inorganic materials 0.000 description 59
• 125000003342 alkenyl group Chemical group 0.000 description 58
• 239000001257 hydrogen Substances 0.000 description 58
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 54
• 150000002431 hydrogen Chemical class 0.000 description 52
• 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 50
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 50
• 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 47
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 45
• KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 description 44
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 42
• DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 42
• 239000010802 sludge Substances 0.000 description 42
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 40
• 125000004549 quinolin-4-yl group Chemical group N1=CC=C(C2=CC=CC=C12)* 0.000 description 40
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 39
• PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 32
• ANTISGAVDLDNTA-UHFFFAOYSA-N 2-methoxyquinazolin-4-amine Chemical compound C1=CC=CC2=NC(OC)=NC(N)=C21 ANTISGAVDLDNTA-UHFFFAOYSA-N 0.000 description 31
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 30
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 30
• 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 29
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 29
• KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 28
• 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 28
• 150000004677 hydrates Chemical class 0.000 description 27
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 23
• 201000010099 disease Diseases 0.000 description 22
• 229910052740 iodine Inorganic materials 0.000 description 22
• 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 21
• 125000004499 isoxazol-5-yl group Chemical group O1N=CC=C1* 0.000 description 20
• 125000003545 alkoxy group Chemical group 0.000 description 19
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 19
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 18
• 229910052736 halogen Inorganic materials 0.000 description 17
• 150000002367 halogens Chemical class 0.000 description 17
• 125000004262 quinoxalin-2-yl group Chemical group [H]C1=NC2=C([H])C([H])=C([H])C([H])=C2N=C1* 0.000 description 17
• 125000003118 aryl group Chemical group 0.000 description 16
• JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 16
• 125000000753 cycloalkyl group Chemical group 0.000 description 16
• 230000000694 effects Effects 0.000 description 16
• 125000001188 haloalkyl group Chemical group 0.000 description 16
• 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 16
• 125000003282 alkyl amino group Chemical group 0.000 description 15
• 125000003710 aryl alkyl group Chemical group 0.000 description 15
• 108091000080 Phosphotransferase Proteins 0.000 description 14
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 14
• METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 14
• 125000004663 dialkyl amino group Chemical group 0.000 description 14
• 125000001072 heteroaryl group Chemical group 0.000 description 14
• 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 14
• 102000020233 phosphotransferase Human genes 0.000 description 14
• 125000000278 alkyl amino alkyl group Chemical group 0.000 description 13
• 125000004103 aminoalkyl group Chemical group 0.000 description 13
• 125000005885 heterocycloalkylalkyl group Chemical group 0.000 description 13
• 125000002768 hydroxyalkyl group Chemical group 0.000 description 13
• YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 13
• 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 12
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 12
• 125000004043 oxo group Chemical group O=* 0.000 description 12
• FBPFZTCFMRRESA-ZXXMMSQZSA-N D-iditol Chemical compound OC[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-ZXXMMSQZSA-N 0.000 description 11
• 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 11
• 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 11
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 11
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 description 10
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 10
• 125000004438 haloalkoxy group Chemical group 0.000 description 10
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 10
• 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 9
• 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 9
• FEHLGOYZDFFMND-UHFFFAOYSA-N cyclopropane-1,1-dicarboxamide Chemical compound NC(=O)C1(C(N)=O)CC1 FEHLGOYZDFFMND-UHFFFAOYSA-N 0.000 description 9
• 239000000203 mixture Substances 0.000 description 9
• 208000011580 syndromic disease Diseases 0.000 description 9
• 239000005711 Benzoic acid Substances 0.000 description 8
• 201000009030 Carcinoma Diseases 0.000 description 8
• 125000004183 alkoxy alkyl group Chemical group 0.000 description 8
• 235000010233 benzoic acid Nutrition 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 8
• 208000035475 disorder Diseases 0.000 description 8
• 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 8
• OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 8
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 8
• 125000004546 quinazolin-4-yl group Chemical group N1=CN=C(C2=CC=CC=C12)* 0.000 description 8
• 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 description 7
• 206010025323 Lymphomas Diseases 0.000 description 7
• 239000002253 acid Substances 0.000 description 7
• 208000009956 adenocarcinoma Diseases 0.000 description 7
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 7
• 239000008194 pharmaceutical composition Substances 0.000 description 7
• 229960004889 salicylic acid Drugs 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• 229940124530 sulfonamide Drugs 0.000 description 7
• 210000004881 tumor cell Anatomy 0.000 description 7
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 6
• 206010039491 Sarcoma Diseases 0.000 description 6
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 6
• 150000001412 amines Chemical class 0.000 description 6
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
• 210000004027 cell Anatomy 0.000 description 6
• 239000003814 drug Substances 0.000 description 6
• 230000007246 mechanism Effects 0.000 description 6
• 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 6
• GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 6
• 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 description 5
• MNXFYMBOTSRGLY-UHFFFAOYSA-N 2-[(3-phenyl-1,2-oxazol-5-yl)methyl]-1H-pyrimidine-2,4-diamine Chemical compound N1C=CC(N)=NC1(N)CC1=CC(C=2C=CC=CC=2)=NO1 MNXFYMBOTSRGLY-UHFFFAOYSA-N 0.000 description 5
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 5
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
• 239000005511 L01XE05 - Sorafenib Substances 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 125000004453 alkoxycarbonyl group Chemical group 0.000 description 5
• 125000003277 amino group Chemical group 0.000 description 5
• 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 5
• 125000006268 biphenyl-3-yl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C1=C([H])C(*)=C([H])C([H])=C1[H] 0.000 description 5
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 5
• 239000002207 metabolite Substances 0.000 description 5
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 5
• 125000004307 pyrazin-2-yl group Chemical group [H]C1=C([H])N=C(*)C([H])=N1 0.000 description 5
• 229960003787 sorafenib Drugs 0.000 description 5
• 206010041823 squamous cell carcinoma Diseases 0.000 description 5
• 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 description 4
• ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 4
• 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
• 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 4
• JLEIRAYWBMNMKU-UHFFFAOYSA-N 3-ethylpentan-3-amine Chemical compound CCC(N)(CC)CC JLEIRAYWBMNMKU-UHFFFAOYSA-N 0.000 description 4
• 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 4
• 125000006305 3-iodophenyl group Chemical group [H]C1=C([H])C(I)=C([H])C(*)=C1[H] 0.000 description 4
• 206010024612 Lipoma Diseases 0.000 description 4
• GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 4
• 241001115903 Raphus cucullatus Species 0.000 description 4
• 101000655609 Streptomyces azureus Thiostrepton Proteins 0.000 description 4
• 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
• 230000036983 biotransformation Effects 0.000 description 4
• 125000004093 cyano group Chemical group *C#N 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• 235000019441 ethanol Nutrition 0.000 description 4
• 150000002632 lipids Chemical class 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 4
• PBQZQTQFQFYBNJ-UHFFFAOYSA-N n-methoxybenzamide Chemical compound CONC(=O)C1=CC=CC=C1 PBQZQTQFQFYBNJ-UHFFFAOYSA-N 0.000 description 4
• 230000037361 pathway Effects 0.000 description 4
• 108090000623 proteins and genes Proteins 0.000 description 4
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 4
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
• 230000019491 signal transduction Effects 0.000 description 4
• YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 4
• YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 4
• 125000004495 thiazol-4-yl group Chemical group S1C=NC(=C1)* 0.000 description 4
• DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 3
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 3
• JTTIOYHBNXDJOD-UHFFFAOYSA-N 2,4,6-triaminopyrimidine Chemical compound NC1=CC(N)=NC(N)=N1 JTTIOYHBNXDJOD-UHFFFAOYSA-N 0.000 description 3
• 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 description 3
• 125000006276 2-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C(*)C([H])=C1[H] 0.000 description 3
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 3
• GELMWIVBBPAMIO-UHFFFAOYSA-N 2-methylbutan-2-amine Chemical compound CCC(C)(C)N GELMWIVBBPAMIO-UHFFFAOYSA-N 0.000 description 3
• JBIHMFNMKHDTEE-UHFFFAOYSA-N 3,4,6,7,8,8a-hexahydro-2h-pyrrolo[1,2-a]pyrazin-1-one Chemical compound O=C1NCCN2CCCC12 JBIHMFNMKHDTEE-UHFFFAOYSA-N 0.000 description 3
• CPDUOSJMCFQXID-UHFFFAOYSA-N 3-(4-chlorophenyl)-1-(3-methylpyridin-2-yl)pyrrolidine-2,5-dione Chemical compound CC1=CC=CN=C1N1C(=O)C(C=2C=CC(Cl)=CC=2)CC1=O CPDUOSJMCFQXID-UHFFFAOYSA-N 0.000 description 3
• VQMPTVQCADWACQ-UHFFFAOYSA-N 3-methylpentan-3-amine Chemical compound CCC(C)(N)CC VQMPTVQCADWACQ-UHFFFAOYSA-N 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
• 244000144725 Amygdalus communis Species 0.000 description 3
• 235000011437 Amygdalus communis Nutrition 0.000 description 3
• 229940122815 Aromatase inhibitor Drugs 0.000 description 3
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
• 244000223760 Cinnamomum zeylanicum Species 0.000 description 3
• XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 3
• XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 3
• 201000008808 Fibrosarcoma Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
• HQMLIDZJXVVKCW-REOHCLBHSA-N L-alaninamide Chemical compound C[C@H](N)C(N)=O HQMLIDZJXVVKCW-REOHCLBHSA-N 0.000 description 3
• 241001465754 Metazoa Species 0.000 description 3
• 208000000035 Osteochondroma Diseases 0.000 description 3
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
• 108091008611 Protein Kinase B Proteins 0.000 description 3
• 230000002159 abnormal effect Effects 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 125000004414 alkyl thio group Chemical group 0.000 description 3
• 235000020224 almond Nutrition 0.000 description 3
• 150000001408 amides Chemical group 0.000 description 3
• 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 3
• 239000003886 aromatase inhibitor Substances 0.000 description 3
• UCMIRNVEIXFBKS-UHFFFAOYSA-M beta-alaninate Chemical compound NCCC([O-])=O UCMIRNVEIXFBKS-UHFFFAOYSA-M 0.000 description 3
• 125000003865 brosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)S(*)(=O)=O 0.000 description 3
• 229960001948 caffeine Drugs 0.000 description 3
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
• 229910052791 calcium Inorganic materials 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 125000004432 carbon atom Chemical group C* 0.000 description 3
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 3
• 229960001231 choline Drugs 0.000 description 3
• 235000017803 cinnamon Nutrition 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 3
• 230000001419 dependent effect Effects 0.000 description 3
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
• 230000004069 differentiation Effects 0.000 description 3
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 3
• 206010016629 fibroma Diseases 0.000 description 3
• 201000011066 hemangioma Diseases 0.000 description 3
• JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 3
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 3
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
• 239000002245 particle Substances 0.000 description 3
• JSSXHAMIXJGYCS-UHFFFAOYSA-N piperazin-4-ium-2-carboxylate Chemical compound OC(=O)C1CNCCN1 JSSXHAMIXJGYCS-UHFFFAOYSA-N 0.000 description 3
• 229910052700 potassium Inorganic materials 0.000 description 3
• 239000011591 potassium Substances 0.000 description 3
• 229940002612 prodrug Drugs 0.000 description 3
• 239000000651 prodrug Substances 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 230000035755 proliferation Effects 0.000 description 3
• BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
• DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• YNVOMSDITJMNET-UHFFFAOYSA-M thiophene-3-carboxylate Chemical compound [O-]C(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-M 0.000 description 3
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
• 230000004614 tumor growth Effects 0.000 description 3
• PTHGDVCPCZKZKR-UHFFFAOYSA-N (4-chlorophenyl)methanol Chemical compound OCC1=CC=C(Cl)C=C1 PTHGDVCPCZKZKR-UHFFFAOYSA-N 0.000 description 2
• 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 2
• DYDZWJOECBIVHD-UHFFFAOYSA-N 1-(3-methylpyridin-2-yl)-3-phenylpyrrolidine-2,5-dione Chemical compound CC1=CC=CN=C1N1C(=O)C(C=2C=CC=CC=2)CC1=O DYDZWJOECBIVHD-UHFFFAOYSA-N 0.000 description 2
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
• 125000004486 1-methylpiperidin-3-yl group Chemical group CN1CC(CCC1)* 0.000 description 2
• 125000004343 1-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C([H])([H])[H] 0.000 description 2
• LGUZCAORVZOCKD-UHFFFAOYSA-N 2-[(3-methyl-1,2-oxazol-5-yl)methyl]-1H-pyrimidine-2,4-diamine Chemical compound CC1=NOC(=C1)CC1(NC=CC(=N1)N)N LGUZCAORVZOCKD-UHFFFAOYSA-N 0.000 description 2
• IQHSSYROJYPFDV-UHFFFAOYSA-N 2-bromo-1,3-dichloro-5-(trifluoromethyl)benzene Chemical group FC(F)(F)C1=CC(Cl)=C(Br)C(Cl)=C1 IQHSSYROJYPFDV-UHFFFAOYSA-N 0.000 description 2
• 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 2
• BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
• 229940013085 2-diethylaminoethanol Drugs 0.000 description 2
• 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 2
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 2
• 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
• 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 2
• 125000001318 4-trifluoromethylbenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(F)(F)F 0.000 description 2
• QVBPHARYACNVKM-UHFFFAOYSA-N 6-methoxyquinazolin-4-amine Chemical compound N1=CN=C(N)C2=CC(OC)=CC=C21 QVBPHARYACNVKM-UHFFFAOYSA-N 0.000 description 2
• VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 2
• NIFBNIANYCOETB-UHFFFAOYSA-N 8-methyl-n-(2-phenylethyl)-8-azabicyclo[3.2.1]octan-3-amine Chemical compound CN1C(C2)CCC1CC2NCCC1=CC=CC=C1 NIFBNIANYCOETB-UHFFFAOYSA-N 0.000 description 2
• NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
• 229940126638 Akt inhibitor Drugs 0.000 description 2
• 201000003076 Angiosarcoma Diseases 0.000 description 2
• 239000004475 Arginine Substances 0.000 description 2
• KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
• 208000003174 Brain Neoplasms Diseases 0.000 description 2
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 2
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
• RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
• RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
• 239000012623 DNA damaging agent Substances 0.000 description 2
• QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
• 239000005977 Ethylene Substances 0.000 description 2
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
• 208000001258 Hemangiosarcoma Diseases 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 208000007766 Kaposi sarcoma Diseases 0.000 description 2
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• FORGMRSGVSYZQR-YFKPBYRVSA-N L-leucinamide Chemical compound CC(C)C[C@H](N)C(N)=O FORGMRSGVSYZQR-YFKPBYRVSA-N 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 2
• 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
• 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
• XNRVGTHNYCNCFF-UHFFFAOYSA-N Lapatinib ditosylate monohydrate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 XNRVGTHNYCNCFF-UHFFFAOYSA-N 0.000 description 2
• 208000018142 Leiomyosarcoma Diseases 0.000 description 2
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• 239000004472 Lysine Substances 0.000 description 2
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
• 208000034578 Multiple myelomas Diseases 0.000 description 2
• KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 2
• UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 2
• 238000005481 NMR spectroscopy Methods 0.000 description 2
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• 201000004681 Psoriasis Diseases 0.000 description 2
• KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
• 208000008383 Wilms tumor Diseases 0.000 description 2
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
• 238000010521 absorption reaction Methods 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 125000006350 alkyl thio alkyl group Chemical group 0.000 description 2
• 125000002947 alkylene group Chemical group 0.000 description 2
• 229910052782 aluminium Inorganic materials 0.000 description 2
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
• 125000002431 aminoalkoxy group Chemical group 0.000 description 2
• 230000000340 anti-metabolite Effects 0.000 description 2
• 230000001946 anti-microtubular Effects 0.000 description 2
• 229940100197 antimetabolite Drugs 0.000 description 2
• 239000002256 antimetabolite Substances 0.000 description 2
• 238000003782 apoptosis assay Methods 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
• 229960003121 arginine Drugs 0.000 description 2
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
• 229940092714 benzenesulfonic acid Drugs 0.000 description 2
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
• 229960003237 betaine Drugs 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000004556 brain Anatomy 0.000 description 2
• GHWVXCQZPNWFRO-UHFFFAOYSA-N butane-2,3-diamine Chemical compound CC(N)C(C)N GHWVXCQZPNWFRO-UHFFFAOYSA-N 0.000 description 2
• 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
• 150000003857 carboxamides Chemical class 0.000 description 2
• 208000002458 carcinoid tumor Diseases 0.000 description 2
• 230000012292 cell migration Effects 0.000 description 2
• 238000002512 chemotherapy Methods 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• 229960004316 cisplatin Drugs 0.000 description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
• 229910052802 copper Inorganic materials 0.000 description 2
• 239000010949 copper Substances 0.000 description 2
• 125000004966 cyanoalkyl group Chemical group 0.000 description 2
• 125000006254 cycloalkyl carbonyl group Chemical group 0.000 description 2
• AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 2
• 239000003995 emulsifying agent Substances 0.000 description 2
• 239000000796 flavoring agent Substances 0.000 description 2
• 235000019634 flavors Nutrition 0.000 description 2
• 125000001207 fluorophenyl group Chemical group 0.000 description 2
• VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 2
• 235000008191 folinic acid Nutrition 0.000 description 2
• 239000011672 folinic acid Substances 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 210000001035 gastrointestinal tract Anatomy 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
• FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid group Chemical group C(CCCCC)(=O)O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
• 238000004128 high performance liquid chromatography Methods 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 229960002885 histidine Drugs 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 230000007062 hydrolysis Effects 0.000 description 2
• 238000006460 hydrolysis reaction Methods 0.000 description 2
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
• 229960002411 imatinib Drugs 0.000 description 2
• 239000007924 injection Substances 0.000 description 2
• 238000002347 injection Methods 0.000 description 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
• 229910052742 iron Inorganic materials 0.000 description 2
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
• AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
• 229940043355 kinase inhibitor Drugs 0.000 description 2
• 229960004891 lapatinib Drugs 0.000 description 2
• 201000010260 leiomyoma Diseases 0.000 description 2
• 229960001691 leucovorin Drugs 0.000 description 2
• 229910052744 lithium Inorganic materials 0.000 description 2
• 229960003646 lysine Drugs 0.000 description 2
• 239000011777 magnesium Substances 0.000 description 2
• 229910052749 magnesium Inorganic materials 0.000 description 2
• WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
• XWQBHJDKCQIWFE-UHFFFAOYSA-N methyl n-[4-chloro-3-(trifluoromethyl)phenyl]carbamate Chemical compound COC(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 XWQBHJDKCQIWFE-UHFFFAOYSA-N 0.000 description 2
• 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 2
• BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
• 229950010895 midostaurin Drugs 0.000 description 2
• 238000013508 migration Methods 0.000 description 2
• NHWSUEIFPBQJDL-UHFFFAOYSA-N n'-(2-phenylethyl)oxamide Chemical compound NC(=O)C(=O)NCCC1=CC=CC=C1 NHWSUEIFPBQJDL-UHFFFAOYSA-N 0.000 description 2
• DFQWLWUEZBTVTD-UHFFFAOYSA-N n-(3,5-dimethoxyphenyl)quinoxalin-2-amine Chemical compound COC1=CC(OC)=CC(NC=2N=C3C=CC=CC3=NC=2)=C1 DFQWLWUEZBTVTD-UHFFFAOYSA-N 0.000 description 2
• 201000008026 nephroblastoma Diseases 0.000 description 2
• 231100000252 nontoxic Toxicity 0.000 description 2
• 230000003000 nontoxic effect Effects 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 201000008968 osteosarcoma Diseases 0.000 description 2
• 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
• WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 2
• 239000000546 pharmaceutical excipient Substances 0.000 description 2
• 125000004344 phenylpropyl group Chemical group 0.000 description 2
• 150000003905 phosphatidylinositols Chemical class 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 2
• 239000000843 powder Substances 0.000 description 2
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
• 229960004919 procaine Drugs 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 230000005522 programmed cell death Effects 0.000 description 2
• TVDSBUOJIPERQY-UHFFFAOYSA-N prop-2-yn-1-ol Chemical compound OCC#C TVDSBUOJIPERQY-UHFFFAOYSA-N 0.000 description 2
• QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
• 239000003197 protein kinase B inhibitor Substances 0.000 description 2
• 150000003212 purines Chemical class 0.000 description 2
• IPEHBUMCGVEMRF-UHFFFAOYSA-N pyrazinecarboxamide Chemical compound NC(=O)C1=CN=CC=N1 IPEHBUMCGVEMRF-UHFFFAOYSA-N 0.000 description 2
• 125000004497 pyrazol-5-yl group Chemical group N1N=CC=C1* 0.000 description 2
• 125000006514 pyridin-2-ylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-O pyridinium Chemical compound C1=CC=[NH+]C=C1 JUJWROOIHBZHMG-UHFFFAOYSA-O 0.000 description 2
• OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 2
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 210000000278 spinal cord Anatomy 0.000 description 2
• 229960001052 streptozocin Drugs 0.000 description 2
• ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 2
• WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
• 229960001796 sunitinib Drugs 0.000 description 2
• 239000000725 suspension Substances 0.000 description 2
• 239000003826 tablet Substances 0.000 description 2
• 229960004559 theobromine Drugs 0.000 description 2
• 238000002560 therapeutic procedure Methods 0.000 description 2
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 2
• YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• 210000004291 uterus Anatomy 0.000 description 2
• 229950000578 vatalanib Drugs 0.000 description 2
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 description 2
• 239000000080 wetting agent Substances 0.000 description 2
• 229910052725 zinc Inorganic materials 0.000 description 2
• 239000011701 zinc Substances 0.000 description 2
• XDEHMKQLKPZERH-BYPYZUCNSA-N (2s)-2-amino-3-methylbutanamide Chemical compound CC(C)[C@H](N)C(N)=O XDEHMKQLKPZERH-BYPYZUCNSA-N 0.000 description 1
• CCENBZDJMALWCH-UHFFFAOYSA-N (4-chlorophenyl) carbamate Chemical compound NC(=O)OC1=CC=C(Cl)C=C1 CCENBZDJMALWCH-UHFFFAOYSA-N 0.000 description 1
• GEZMEIHVFSWOCA-UHFFFAOYSA-N (4-fluorophenyl)methanol Chemical compound OCC1=CC=C(F)C=C1 GEZMEIHVFSWOCA-UHFFFAOYSA-N 0.000 description 1
• 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 description 1
• 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 description 1
• MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
• SYKLNLIUTCAYCR-UHFFFAOYSA-N (sulfamoylamino)methylbenzene Chemical compound NS(=O)(=O)NCC1=CC=CC=C1 SYKLNLIUTCAYCR-UHFFFAOYSA-N 0.000 description 1
• ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
• 125000001414 1,2,4-triazol-5-yl group Chemical group [H]N1N=C([H])N=C1[*] 0.000 description 1
• 125000004509 1,3,4-oxadiazol-2-yl group Chemical group O1C(=NN=C1)* 0.000 description 1
• NFDGJMKNCHPJKF-UHFFFAOYSA-N 1-(3-methylphenyl)-3-(4-methylphenyl)sulfonyl-2h-imidazo[4,5-b]quinoxaline Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC3=CC=CC=C3N=C2N(C=2C=C(C)C=CC=2)C1 NFDGJMKNCHPJKF-UHFFFAOYSA-N 0.000 description 1
• YXZQVRUKGQOZIP-UHFFFAOYSA-N 1-(4-methoxyphenyl)-3-(4-methylphenyl)sulfonyl-2h-imidazo[4,5-b]quinoxaline Chemical compound C1=CC(OC)=CC=C1N1C2=NC3=CC=CC=C3N=C2N(S(=O)(=O)C=2C=CC(C)=CC=2)C1 YXZQVRUKGQOZIP-UHFFFAOYSA-N 0.000 description 1
• LBGCXZFAWMNACS-UHFFFAOYSA-N 1-(4-methylphenyl)-3-(3-nitrophenyl)sulfonyl-2h-imidazo[4,5-b]quinoxaline Chemical compound C1=CC(C)=CC=C1N1C2=NC3=CC=CC=C3N=C2N(S(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)C1 LBGCXZFAWMNACS-UHFFFAOYSA-N 0.000 description 1
• PWMWNFMRSKOCEY-UHFFFAOYSA-N 1-Phenyl-1,2-ethanediol Chemical compound OCC(O)C1=CC=CC=C1 PWMWNFMRSKOCEY-UHFFFAOYSA-N 0.000 description 1
• YGRIEMSMFNEFKK-UHFFFAOYSA-N 1-[3-[[4-(3,4-dichloroanilino)-6-methoxyquinazolin-7-yl]oxymethyl]-4-ethylpiperazin-1-yl]ethanone Chemical compound CCN1CCN(C(C)=O)CC1COC1=CC2=NC=NC(NC=3C=C(Cl)C(Cl)=CC=3)=C2C=C1OC YGRIEMSMFNEFKK-UHFFFAOYSA-N 0.000 description 1
• FGOBYJLJQMACOY-UHFFFAOYSA-N 1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(2-phenylacetyl)imidazolidin-2-one Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1N(C1=O)CCN1C(=O)CC1=CC=CC=C1 FGOBYJLJQMACOY-UHFFFAOYSA-N 0.000 description 1
• QOMCTMPSURDRBN-UHFFFAOYSA-N 1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]imidazolidin-2-one Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1N1CCNC1=O QOMCTMPSURDRBN-UHFFFAOYSA-N 0.000 description 1
• CTMKMZYTPUDEDG-UHFFFAOYSA-N 1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]piperidin-2-one Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1N1CCCCC1=O CTMKMZYTPUDEDG-UHFFFAOYSA-N 0.000 description 1
• MRXUDWFSOWSQJI-UHFFFAOYSA-N 1-benzyl-3-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]imidazolidin-2-one Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1N(C1=O)CCN1CC1=CC=CC=C1 MRXUDWFSOWSQJI-UHFFFAOYSA-N 0.000 description 1
• CHXUFRRQOZZSNV-UHFFFAOYSA-N 1-methylpiperidine Chemical compound [CH2]N1CCCCC1 CHXUFRRQOZZSNV-UHFFFAOYSA-N 0.000 description 1
• RELUQOFVQCRUDB-UHFFFAOYSA-N 1-naphthalen-2-yl-3-(3-nitrophenyl)sulfonyl-2h-imidazo[4,5-b]quinoxaline Chemical compound [O-][N+](=O)C1=CC=CC(S(=O)(=O)N2C3=NC4=CC=CC=C4N=C3N(C2)C=2C=C3C=CC=CC3=CC=2)=C1 RELUQOFVQCRUDB-UHFFFAOYSA-N 0.000 description 1
• 125000001088 1-naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
• 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• WRMZOPANDOHWJU-UHFFFAOYSA-N 1h-indol-6-ylmethanol Chemical compound OCC1=CC=C2C=CNC2=C1 WRMZOPANDOHWJU-UHFFFAOYSA-N 0.000 description 1
• 125000004778 2,2-difluoroethyl group Chemical group [H]C([H])(*)C([H])(F)F 0.000 description 1
• NXAFZORDAOCSCX-UHFFFAOYSA-N 2,3-dichloro-n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]benzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C(=C(Cl)C=CC=3)Cl)C=CC=2)=C1 NXAFZORDAOCSCX-UHFFFAOYSA-N 0.000 description 1
• WLUTWUXFPVJQHJ-UHFFFAOYSA-N 2,5-dichloro-n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]benzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C(=CC=C(Cl)C=3)Cl)C=CC=2)=C1 WLUTWUXFPVJQHJ-UHFFFAOYSA-N 0.000 description 1
• 125000003070 2-(2-chlorophenyl)ethyl group Chemical group [H]C1=C([H])C(Cl)=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• MUAXWDHYFWDBJL-UHFFFAOYSA-N 2-(3-chloro-2-fluorophenyl)-3-hydroxy-3-[2-(pyridin-2-ylamino)-3h-benzimidazol-5-yl]isoindol-1-one Chemical compound O=C1C2=CC=CC=C2C(O)(C=2C=C3N=C(NC=4N=CC=CC=4)NC3=CC=2)N1C1=CC=CC(Cl)=C1F MUAXWDHYFWDBJL-UHFFFAOYSA-N 0.000 description 1
• CBBFWSMELCDMPZ-UHFFFAOYSA-N 2-(methylamino)acetamide Chemical compound CNCC(N)=O CBBFWSMELCDMPZ-UHFFFAOYSA-N 0.000 description 1
• KTFDYVNEGTXQCV-UHFFFAOYSA-N 2-Thiophenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CS1 KTFDYVNEGTXQCV-UHFFFAOYSA-N 0.000 description 1
• VUWFQGJGPWCUFD-UHFFFAOYSA-N 2-[(3-ethyl-1,2-oxazol-5-yl)methyl]-1H-pyrimidine-2,4-diamine Chemical compound CCc1cc(CC2(N)NC=CC(N)=N2)on1 VUWFQGJGPWCUFD-UHFFFAOYSA-N 0.000 description 1
• NLUZLIGNJYSHLP-UHFFFAOYSA-N 2-[(3-methyl-1,2-oxazol-5-yl)methyl]-6-morpholin-4-yl-1H-pyrimidine-2,4-diamine Chemical compound Cc1cc(CC2(N)NC(=CC(N)=N2)N2CCOCC2)on1 NLUZLIGNJYSHLP-UHFFFAOYSA-N 0.000 description 1
• UHINABAHWQOUEE-UHFFFAOYSA-N 2-[(3-pyrimidin-4-yl-1,2-oxazol-5-yl)methyl]-1H-pyrimidine-2,4-diamine Chemical compound N1C=CC(N)=NC1(N)CC1=CC(C=2N=CN=CC=2)=NO1 UHINABAHWQOUEE-UHFFFAOYSA-N 0.000 description 1
• ZYHQGITXIJDDKC-UHFFFAOYSA-N 2-[2-(2-aminophenyl)ethyl]aniline Chemical group NC1=CC=CC=C1CCC1=CC=CC=C1N ZYHQGITXIJDDKC-UHFFFAOYSA-N 0.000 description 1
• KCGTXHCPPMDHIJ-UHFFFAOYSA-N 2-[2-[4-(3,4-dichloroanilino)-6-methoxyquinazolin-7-yl]oxyethyl]isoindole-1,3-dione Chemical compound N1=CN=C2C=C(OCCN3C(C4=CC=CC=C4C3=O)=O)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1 KCGTXHCPPMDHIJ-UHFFFAOYSA-N 0.000 description 1
• HENKTRFJYRXSTF-UHFFFAOYSA-N 2-[2-[[4-(3,4-dichloroanilino)-6-methoxyquinazolin-7-yl]oxymethyl]morpholin-4-yl]-1-phenylethanone Chemical compound N1=CN=C2C=C(OCC3OCCN(CC(=O)C=4C=CC=CC=4)C3)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1 HENKTRFJYRXSTF-UHFFFAOYSA-N 0.000 description 1
• VDZJXBQVKQBAMH-UHFFFAOYSA-N 2-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]anilino]-2-methylpropanamide Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(C)(C)C(N)=O)C=CC=2)=C1 VDZJXBQVKQBAMH-UHFFFAOYSA-N 0.000 description 1
• JTENXCVOBNQPFW-UHFFFAOYSA-N 2-[[3-(4-fluorophenyl)-1,2-oxazol-5-yl]methyl]-6-(4-methylpiperazin-1-yl)-1H-pyrimidine-2,4-diamine Chemical compound C1CN(C)CCN1C(N1)=CC(N)=NC1(N)CC1=CC(C=2C=CC(F)=CC=2)=NO1 JTENXCVOBNQPFW-UHFFFAOYSA-N 0.000 description 1
• MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
• PAVGKEQNUONORK-UHFFFAOYSA-N 2-amino-n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)N)C=CC=2)=C1 PAVGKEQNUONORK-UHFFFAOYSA-N 0.000 description 1
• GXBRYTMUEZNYJT-UHFFFAOYSA-N 2-anilinoacetamide Chemical compound NC(=O)CNC1=CC=CC=C1 GXBRYTMUEZNYJT-UHFFFAOYSA-N 0.000 description 1
• GWVCKDGKNUDQHN-UHFFFAOYSA-N 2-benzyl-3-hydroxy-3-(1h-indazol-5-yl)isoindol-1-one Chemical compound O=C1C2=CC=CC=C2C(O)(C=2C=C3C=NNC3=CC=2)N1CC1=CC=CC=C1 GWVCKDGKNUDQHN-UHFFFAOYSA-N 0.000 description 1
• OYISWWNIAMMJSR-UHFFFAOYSA-N 2-benzyl-3-hydroxy-3-(1h-indazol-6-yl)isoindol-1-one Chemical compound O=C1C2=CC=CC=C2C(O)(C=2C=C3NN=CC3=CC=2)N1CC1=CC=CC=C1 OYISWWNIAMMJSR-UHFFFAOYSA-N 0.000 description 1
• 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
• FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
• 125000000872 2-diethylaminoethoxy group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
• GKTFLKJXZOYBRW-UHFFFAOYSA-N 2-ethylbenzamide Chemical compound CCC1=CC=CC=C1C(N)=O GKTFLKJXZOYBRW-UHFFFAOYSA-N 0.000 description 1
• 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
• ZTVIKZXZYLEVOL-DGKWVBSXSA-N 2-hydroxy-2-phenylacetic acid [(1R,5S)-8-methyl-8-azabicyclo[3.2.1]octan-3-yl] ester Chemical group C([C@H]1CC[C@@H](C2)N1C)C2OC(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-DGKWVBSXSA-N 0.000 description 1
• 125000006304 2-iodophenyl group Chemical group [H]C1=C([H])C(I)=C(*)C([H])=C1[H] 0.000 description 1
• 125000002927 2-methoxybenzyl group Chemical group [H]C1=C([H])C([H])=C(C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
• 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
• 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
• BWYJJZBRYSADRP-UHFFFAOYSA-N 2-methoxyquinazoline Chemical compound C1=CC=CC2=NC(OC)=NC=C21 BWYJJZBRYSADRP-UHFFFAOYSA-N 0.000 description 1
• 125000006179 2-methyl benzyl group Chemical group [H]C1=C([H])C(=C(C([H])=C1[H])C([H])([H])*)C([H])([H])[H] 0.000 description 1
• XXUNIGZDNWWYED-UHFFFAOYSA-N 2-methylbenzamide Chemical compound CC1=CC=CC=C1C(N)=O XXUNIGZDNWWYED-UHFFFAOYSA-N 0.000 description 1
• MIKNSPXOIZYKIT-UHFFFAOYSA-N 2-methylbutane-2,3-diamine Chemical compound CC(N)C(C)(C)N MIKNSPXOIZYKIT-UHFFFAOYSA-N 0.000 description 1
• CGRKYGKHZOCPSZ-UHFFFAOYSA-N 2-methylpropanediamide Chemical compound NC(=O)C(C)C(N)=O CGRKYGKHZOCPSZ-UHFFFAOYSA-N 0.000 description 1
• FJNLCHNQVJVCPY-UHFFFAOYSA-N 2-n-methoxy-2-n-methyl-4-n,6-n-dipropyl-1,3,5-triazine-2,4,6-triamine Chemical compound CCCNC1=NC(NCCC)=NC(N(C)OC)=N1 FJNLCHNQVJVCPY-UHFFFAOYSA-N 0.000 description 1
• GNDKYAWHEKZHPJ-UHFFFAOYSA-N 2-nitrobenzenesulfonimidic acid Chemical compound NS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O GNDKYAWHEKZHPJ-UHFFFAOYSA-N 0.000 description 1
• XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-pyridylethylamine Chemical compound NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 description 1
• 125000006499 2-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(OC(F)(F)F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
• 125000006494 2-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C([H])=C(C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 1
• CGNJNFZTDWGNSF-UHFFFAOYSA-N 2h-pyrimidin-1-amine Chemical compound NN1CN=CC=C1 CGNJNFZTDWGNSF-UHFFFAOYSA-N 0.000 description 1
• GCAZYLADJZHVJR-UHFFFAOYSA-N 3,3-diethylpentanediamide Chemical compound C(C)C(CC(=O)N)(CC(=O)N)CC GCAZYLADJZHVJR-UHFFFAOYSA-N 0.000 description 1
• GKHPIRGWVRGHIG-UHFFFAOYSA-N 3,4-dichloro-n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]benzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C=C(Cl)C(Cl)=CC=3)C=CC=2)=C1 GKHPIRGWVRGHIG-UHFFFAOYSA-N 0.000 description 1
• 125000006509 3,4-difluorobenzyl group Chemical group [H]C1=C(F)C(F)=C([H])C(=C1[H])C([H])([H])* 0.000 description 1
• NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
• 125000006288 3,5-difluorobenzyl group Chemical group [H]C1=C(F)C([H])=C(C([H])=C1F)C([H])([H])* 0.000 description 1
• LJGHYPLBDBRCRZ-UHFFFAOYSA-N 3-(3-aminophenyl)sulfonylaniline Chemical group NC1=CC=CC(S(=O)(=O)C=2C=C(N)C=CC=2)=C1 LJGHYPLBDBRCRZ-UHFFFAOYSA-N 0.000 description 1
• JDZWNQFNSIMKDH-UHFFFAOYSA-N 3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]benzoic acid Chemical compound COC1=CC=C(Cl)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)C(O)=O)=C1 JDZWNQFNSIMKDH-UHFFFAOYSA-N 0.000 description 1
• UPWRPIZWKHGRFC-UHFFFAOYSA-N 3-[[3-[(3-nitrophenyl)sulfonylamino]quinoxalin-2-yl]amino]benzoic acid Chemical compound OC(=O)C1=CC=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 UPWRPIZWKHGRFC-UHFFFAOYSA-N 0.000 description 1
• VCTZLTPHOLABIJ-UHFFFAOYSA-N 3-[[3-[(4-methylphenyl)sulfonylamino]quinoxalin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC1=CC=CC(S(N)(=O)=O)=C1 VCTZLTPHOLABIJ-UHFFFAOYSA-N 0.000 description 1
• IGZWBYQSQLIIJW-UHFFFAOYSA-N 3-[[3-[(4-methylphenyl)sulfonylamino]quinoxalin-2-yl]amino]benzoic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC1=CC=CC(C(O)=O)=C1 IGZWBYQSQLIIJW-UHFFFAOYSA-N 0.000 description 1
• DWKPZTIHSIMXGM-UHFFFAOYSA-N 3-[[3-[[4-(dihydroxyamino)phenyl]sulfonylamino]quinoxalin-2-yl]amino]benzoic acid Chemical compound C1=CC(N(O)O)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC1=CC=CC(C(O)=O)=C1 DWKPZTIHSIMXGM-UHFFFAOYSA-N 0.000 description 1
• MGXITTNHTOUXCK-UHFFFAOYSA-N 3-chloro-n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]benzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C=C(Cl)C=CC=3)C=CC=2)=C1 MGXITTNHTOUXCK-UHFFFAOYSA-N 0.000 description 1
• PWNBOXHERFDQGS-UHFFFAOYSA-N 3-hydroxy-2-(3-methoxyphenyl)-3-[2-(pyrazin-2-ylamino)-3h-benzimidazol-5-yl]isoindol-1-one Chemical compound COC1=CC=CC(N2C(C3=CC=CC=C3C2=O)(O)C=2C=C3N=C(NC=4N=CC=NC=4)NC3=CC=2)=C1 PWNBOXHERFDQGS-UHFFFAOYSA-N 0.000 description 1
• 125000006497 3-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC([H])([H])[H])=C1[H])C([H])([H])* 0.000 description 1
• 125000006180 3-methyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])[H])C([H])([H])* 0.000 description 1
• MCAXOOCHYNKTRY-UHFFFAOYSA-N 3-phenylpropane-1-sulfonamide Chemical compound NS(=O)(=O)CCCC1=CC=CC=C1 MCAXOOCHYNKTRY-UHFFFAOYSA-N 0.000 description 1
• GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 description 1
• 125000006500 3-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(=C([H])C(OC(F)(F)F)=C1[H])C([H])([H])* 0.000 description 1
• 125000006495 3-trifluoromethyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C(=C1[H])C([H])([H])*)C(F)(F)F 0.000 description 1
• OXKGFXZLEVBMRZ-UHFFFAOYSA-N 4-(2-cyclohexylethyl)-2-[[4-[(3,4-dichlorophenyl)methyl]-6-methoxyquinazolin-7-yl]oxymethyl]-1,4-oxazepane Chemical compound N1=CN=C2C=C(OCC3OCCCN(CCC4CCCCC4)C3)C(OC)=CC2=C1CC1=CC=C(Cl)C(Cl)=C1 OXKGFXZLEVBMRZ-UHFFFAOYSA-N 0.000 description 1
• OOGRHMWWVSLRGA-UHFFFAOYSA-N 4-(cyclohexylmethyl)-2-[[4-[(3,4-dichlorophenyl)methyl]-6-methoxyquinazolin-7-yl]oxymethyl]-1,4-oxazepane Chemical compound N1=CN=C2C=C(OCC3OCCCN(CC4CCCCC4)C3)C(OC)=CC2=C1CC1=CC=C(Cl)C(Cl)=C1 OOGRHMWWVSLRGA-UHFFFAOYSA-N 0.000 description 1
• GWRSATNRNFYMDI-UHFFFAOYSA-N 4-[(9-cyclopentyl-7,7-difluoro-5-methyl-6-oxo-8h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methylpiperidin-4-yl)benzamide Chemical compound FC=1C=C(NC=2N=C3N(C4CCCC4)CC(F)(F)C(=O)N(C)C3=CN=2)C(OC)=CC=1C(=O)NC1CCN(C)CC1 GWRSATNRNFYMDI-UHFFFAOYSA-N 0.000 description 1
• MLIZWELCMQRQMI-UNXLUWIOSA-N 4-[(E)-2-[3-(4-chlorophenyl)-1H-pyrazol-5-yl]ethenyl]phenol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(C=2C=CC(Cl)=CC=2)=NN1 MLIZWELCMQRQMI-UNXLUWIOSA-N 0.000 description 1
• DSLMHMBHXDLJQB-UNXLUWIOSA-N 4-[(E)-2-[3-(4-fluorophenyl)-1H-pyrazol-5-yl]ethenyl]phenol Chemical compound C1=CC(O)=CC=C1\C=C\C1=NNC(C=2C=CC(F)=CC=2)=C1 DSLMHMBHXDLJQB-UNXLUWIOSA-N 0.000 description 1
• GQVBUIUWBXICGT-UHFFFAOYSA-N 4-[4-(4-benzylpiperidin-1-yl)phenoxy]-6,7-dimethoxyquinoline Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1N(CC1)CCC1CC1=CC=CC=C1 GQVBUIUWBXICGT-UHFFFAOYSA-N 0.000 description 1
• LLYCEAVVAGEZLB-UHFFFAOYSA-N 4-[6-[(5-cyclopropyl-1h-pyrazol-3-yl)amino]-2-[(3-propan-2-yl-1,2-oxazol-5-yl)methylamino]pyrimidin-4-yl]piperazine-1-carbaldehyde Chemical compound O1N=C(C(C)C)C=C1CNC1=NC(NC2=NNC(=C2)C2CC2)=CC(N2CCN(CC2)C=O)=N1 LLYCEAVVAGEZLB-UHFFFAOYSA-N 0.000 description 1
• HBRCKKRDKWTFFP-UHFFFAOYSA-N 4-[[3-(benzenesulfonamido)quinoxalin-2-yl]amino]-2-hydroxybenzoic acid Chemical compound C1=C(O)C(C(=O)O)=CC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 HBRCKKRDKWTFFP-UHFFFAOYSA-N 0.000 description 1
• RXGNLKDXFQJQCN-UHFFFAOYSA-N 4-[[3-(benzenesulfonamido)quinoxalin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1 RXGNLKDXFQJQCN-UHFFFAOYSA-N 0.000 description 1
• LTWYLEHAQYYVSL-UHFFFAOYSA-N 4-[[3-[(3-nitrophenyl)sulfonylamino]quinoxalin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 LTWYLEHAQYYVSL-UHFFFAOYSA-N 0.000 description 1
• AZYFTAYNMPTQPL-UHFFFAOYSA-N 4-[[3-[(4-acetamidophenyl)sulfonylamino]quinoxalin-2-yl]amino]benzoic acid Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC1=CC=C(C(O)=O)C=C1 AZYFTAYNMPTQPL-UHFFFAOYSA-N 0.000 description 1
• YXNMKLBKSSVUBF-UHFFFAOYSA-N 4-[[3-[(4-bromophenyl)sulfonylamino]quinoxalin-2-yl]amino]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(Br)C=C1 YXNMKLBKSSVUBF-UHFFFAOYSA-N 0.000 description 1
• QDQSHWYDGZAZAV-UHFFFAOYSA-N 4-[[3-[(4-methylphenyl)sulfonylamino]quinoxalin-2-yl]amino]benzoic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC1=CC=C(C(O)=O)C=C1 QDQSHWYDGZAZAV-UHFFFAOYSA-N 0.000 description 1
• BQZSITGLBLNHBE-UHFFFAOYSA-N 4-benzyl-1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]-3-(4-methylphenyl)sulfonylimidazolidin-2-one Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1N(C(N1S(=O)(=O)C=2C=CC(C)=CC=2)=O)CC1CC1=CC=CC=C1 BQZSITGLBLNHBE-UHFFFAOYSA-N 0.000 description 1
• DFFYYHCIQMERJE-UHFFFAOYSA-N 4-benzyl-1-[4-(6,7-dimethoxyquinolin-4-yl)oxy-3-fluorophenyl]imidazolidin-2-one Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C(=C1)F)=CC=C1N(C(N1)=O)CC1CC1=CC=CC=C1 DFFYYHCIQMERJE-UHFFFAOYSA-N 0.000 description 1
• VWIYIAHIOHEFJL-UHFFFAOYSA-N 4-benzyl-1-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1,3-diazinan-2-one Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1N(C(N1)=O)CCC1CC1=CC=CC=C1 VWIYIAHIOHEFJL-UHFFFAOYSA-N 0.000 description 1
• XQALDUDLHLHAOH-UHFFFAOYSA-N 4-benzyl-1-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]imidazolidin-2-one Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1N(C(N1)=O)CC1CC1=CC=CC=C1 XQALDUDLHLHAOH-UHFFFAOYSA-N 0.000 description 1
• DLXLPGRDLGVFAP-UHFFFAOYSA-N 4-benzyl-1-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]piperazin-2-one Chemical compound C=12C=C(OC)C(OC)=CC2=NC=CC=1OC(C=C1)=CC=C1N(C(C1)=O)CCN1CC1=CC=CC=C1 DLXLPGRDLGVFAP-UHFFFAOYSA-N 0.000 description 1
• PBHBDGBULFUYPA-UHFFFAOYSA-N 4-bromo-n-[3-(2,5-dimethoxyanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound COC1=CC=C(OC)C(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC(Br)=CC=2)=C1 PBHBDGBULFUYPA-UHFFFAOYSA-N 0.000 description 1
• AHFINSWGYAZBOZ-UHFFFAOYSA-N 4-chloro-2-(trifluoromethyl)benzaldehyde Chemical group FC(F)(F)C1=CC(Cl)=CC=C1C=O AHFINSWGYAZBOZ-UHFFFAOYSA-N 0.000 description 1
• PWQVTECCGKENBM-UHFFFAOYSA-N 4-chloro-n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]benzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C=CC(Cl)=CC=3)C=CC=2)=C1 PWQVTECCGKENBM-UHFFFAOYSA-N 0.000 description 1
• AVPYQKSLYISFPO-UHFFFAOYSA-N 4-chlorobenzaldehyde Chemical compound ClC1=CC=C(C=O)C=C1 AVPYQKSLYISFPO-UHFFFAOYSA-N 0.000 description 1
• RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
• 125000004860 4-ethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])C([H])([H])[H] 0.000 description 1
• UOQXIWFBQSVDPP-UHFFFAOYSA-N 4-fluorobenzaldehyde Chemical compound FC1=CC=C(C=O)C=C1 UOQXIWFBQSVDPP-UHFFFAOYSA-N 0.000 description 1
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
• SNLFYGIUTYKKOE-UHFFFAOYSA-N 4-n,4-n-bis(4-aminophenyl)benzene-1,4-diamine Chemical compound C1=CC(N)=CC=C1N(C=1C=CC(N)=CC=1)C1=CC=C(N)C=C1 SNLFYGIUTYKKOE-UHFFFAOYSA-N 0.000 description 1
• 125000000173 4-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC(F)(F)F)C([H])([H])* 0.000 description 1
• VATKWVNDCITFEB-UHFFFAOYSA-N 5-[2-[[4-(3,4-dichloroanilino)-6-methoxyquinazolin-7-yl]oxymethyl]-1,3-thiazol-4-yl]-2-hydroxybenzamide Chemical compound N1=CN=C2C=C(OCC=3SC=C(N=3)C=3C=C(C(O)=CC=3)C(N)=O)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1 VATKWVNDCITFEB-UHFFFAOYSA-N 0.000 description 1
• IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
• PCDPMVJGEGAJBI-UHFFFAOYSA-N 6,7-dimethoxyquinoline Chemical compound C1=CN=C2C=C(OC)C(OC)=CC2=C1 PCDPMVJGEGAJBI-UHFFFAOYSA-N 0.000 description 1
• ORYJVRQYSMBITC-UHFFFAOYSA-N 6-(6,7-dimethoxyquinolin-4-yl)oxy-1,3-benzothiazol-2-amine Chemical compound C1=C2N=C(N)SC2=CC(OC=2C=CN=C3C=C(C(=CC3=2)OC)OC)=C1 ORYJVRQYSMBITC-UHFFFAOYSA-N 0.000 description 1
• WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
• ONNASYFWYZONLS-UHFFFAOYSA-N 6-[1-hydroxy-3-oxo-2-[3-(trifluoromethyl)phenyl]isoindol-1-yl]-4h-1,4-benzoxazin-3-one Chemical compound O=C1C2=CC=CC=C2C(O)(C=2C=C3NC(=O)COC3=CC=2)N1C1=CC=CC(C(F)(F)F)=C1 ONNASYFWYZONLS-UHFFFAOYSA-N 0.000 description 1
• VSZVLZXSAYSPHV-UHFFFAOYSA-N 6-[2-(1h-benzimidazol-2-yl)benzoyl]-4h-1,4-benzoxazin-3-one Chemical compound C1=CC=C2NC(C3=CC=CC=C3C(C=3C=C4NC(=O)COC4=CC=3)=O)=NC2=C1 VSZVLZXSAYSPHV-UHFFFAOYSA-N 0.000 description 1
• LMJWLZOUEZKFHO-UHFFFAOYSA-N 6-[2-(3-amino-5-chlorophenyl)-1-hydroxy-3-oxoisoindol-1-yl]-4h-1,4-benzoxazin-3-one Chemical compound NC1=CC(Cl)=CC(N2C(C3=CC=CC=C3C2=O)(O)C=2C=C3NC(=O)COC3=CC=2)=C1 LMJWLZOUEZKFHO-UHFFFAOYSA-N 0.000 description 1
• RWZGTKNZCVARNP-UHFFFAOYSA-N 6-[2-(3-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-4h-1,4-benzoxazin-3-one Chemical compound CC1=C(Cl)C=CC=C1N1C(C=2C=C3NC(=O)COC3=CC=2)(O)C2=CC=CC=C2C1=O RWZGTKNZCVARNP-UHFFFAOYSA-N 0.000 description 1
• BOYORSYSOCEJAM-UHFFFAOYSA-N 6-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)benzoyl]-4h-1,4-benzoxazin-3-one Chemical compound C=1C=C2OCC(=O)NC2=CC=1C(=O)C1=CC=CC=C1C(ON=1)=NC=1C1=CC=CC=C1 BOYORSYSOCEJAM-UHFFFAOYSA-N 0.000 description 1
• KKWVJTOMPUCLJP-UHFFFAOYSA-N 6-[2-(5-chloro-2-methoxyphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-4h-1,4-benzoxazin-3-one Chemical compound COC1=CC=C(Cl)C=C1N1C(C=2C=C3NC(=O)COC3=CC=2)(O)C2=CC=CC=C2C1=O KKWVJTOMPUCLJP-UHFFFAOYSA-N 0.000 description 1
• GCQSTRCSTKDJPL-UHFFFAOYSA-N 6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-4h-1,4-benzoxazin-3-one Chemical compound CC1=CC=C(Cl)C=C1N1C(C=2C=C3NC(=O)COC3=CC=2)(O)C2=CC=CC=C2C1=O GCQSTRCSTKDJPL-UHFFFAOYSA-N 0.000 description 1
• PTIUMPLMKWFQCQ-UHFFFAOYSA-N 6-[2-[(3,4-dichlorophenyl)methyl]-1-hydroxy-3-oxoisoindol-1-yl]-4h-1,4-benzoxazin-3-one Chemical compound O=C1C2=CC=CC=C2C(O)(C=2C=C3NC(=O)COC3=CC=2)N1CC1=CC=C(Cl)C(Cl)=C1 PTIUMPLMKWFQCQ-UHFFFAOYSA-N 0.000 description 1
• IQFNNPBWPNNACU-UHFFFAOYSA-N 6-[4-(4-chlorophenyl)piperazin-1-yl]-7h-purine Chemical compound C1=CC(Cl)=CC=C1N1CCN(C=2C=3N=CNC=3N=CN=2)CC1 IQFNNPBWPNNACU-UHFFFAOYSA-N 0.000 description 1
• XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
• CPAWJWKJKMWUDJ-UHFFFAOYSA-N 6-methoxy-7-[(4-pentyl-1,4-oxazepan-2-yl)methoxy]quinazolin-4-amine Chemical compound C1N(CCCCC)CCCOC1COC1=CC2=NC=NC(N)=C2C=C1OC CPAWJWKJKMWUDJ-UHFFFAOYSA-N 0.000 description 1
• VNWFBKPSJIUMPW-UHFFFAOYSA-N 8-[[3-[(4-methylphenyl)sulfonylamino]quinoxalin-2-yl]amino]quinoline-2-carboxylic acid Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC1=CC=CC2=CC=C(C(O)=O)N=C12 VNWFBKPSJIUMPW-UHFFFAOYSA-N 0.000 description 1
• OONFNUWBHFSNBT-HXUWFJFHSA-N AEE788 Chemical compound C1CN(CC)CCN1CC1=CC=C(C=2NC3=NC=NC(N[C@H](C)C=4C=CC=CC=4)=C3C=2)C=C1 OONFNUWBHFSNBT-HXUWFJFHSA-N 0.000 description 1
• BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 description 1
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
• 206010001233 Adenoma benign Diseases 0.000 description 1
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
• 206010003571 Astrocytoma Diseases 0.000 description 1
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
• QULDDKSCVCJTPV-UHFFFAOYSA-N BIIB021 Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QULDDKSCVCJTPV-UHFFFAOYSA-N 0.000 description 1
• 206010004146 Basal cell carcinoma Diseases 0.000 description 1
• LRHPLDYGYMQRHN-UHFFFAOYSA-N Butanol Natural products CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
• 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
• NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
• XJCFWZTVRCXDDA-UHFFFAOYSA-N C1=C(O)C(C(=O)O)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC=CC=2)=C1 Chemical compound C1=C(O)C(C(=O)O)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC=CC=2)=C1 XJCFWZTVRCXDDA-UHFFFAOYSA-N 0.000 description 1
• BZOPIXHIHBEHNK-UHFFFAOYSA-N C1=CC(C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC1=CC=C(O)C(C(O)=O)=C1 Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC1=CC=C(O)C(C(O)=O)=C1 BZOPIXHIHBEHNK-UHFFFAOYSA-N 0.000 description 1
• 101100371682 Caenorhabditis elegans cyk-3 gene Proteins 0.000 description 1
• 101100545272 Caenorhabditis elegans zif-1 gene Proteins 0.000 description 1
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
• 208000009458 Carcinoma in Situ Diseases 0.000 description 1
• 206010008263 Cervical dysplasia Diseases 0.000 description 1
• 201000005262 Chondroma Diseases 0.000 description 1
• 208000005243 Chondrosarcoma Diseases 0.000 description 1
• 208000006332 Choriocarcinoma Diseases 0.000 description 1
• PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
• 206010048832 Colon adenoma Diseases 0.000 description 1
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
• 206010012689 Diabetic retinopathy Diseases 0.000 description 1
• 206010013710 Drug interaction Diseases 0.000 description 1
• 206010014967 Ependymoma Diseases 0.000 description 1
• 102000009024 Epidermal Growth Factor Human genes 0.000 description 1
• 101800003838 Epidermal growth factor Proteins 0.000 description 1
• PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 208000007659 Fibroadenoma Diseases 0.000 description 1
• 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
• MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
• 208000023783 Genitourinary tract disease Diseases 0.000 description 1
• 208000007569 Giant Cell Tumors Diseases 0.000 description 1
• 208000032612 Glial tumor Diseases 0.000 description 1
• 206010018338 Glioma Diseases 0.000 description 1
• 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 244000068988 Glycine max Species 0.000 description 1
• 235000010469 Glycine max Nutrition 0.000 description 1
• 206010018691 Granuloma Diseases 0.000 description 1
• 208000002927 Hamartoma Diseases 0.000 description 1
• 206010019629 Hepatic adenoma Diseases 0.000 description 1
• 102100027368 Histone H1.3 Human genes 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• 101001009450 Homo sapiens Histone H1.3 Proteins 0.000 description 1
• 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
• 102000004877 Insulin Human genes 0.000 description 1
• 108090001061 Insulin Proteins 0.000 description 1
• 101150092727 KLF10 gene Proteins 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
• VLJNHYLEOZPXFW-BYPYZUCNSA-N L-prolinamide Chemical compound NC(=O)[C@@H]1CCCN1 VLJNHYLEOZPXFW-BYPYZUCNSA-N 0.000 description 1
• 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
• 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
• 239000003798 L01XE11 - Pazopanib Substances 0.000 description 1
• 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 102000029749 Microtubule Human genes 0.000 description 1
• 108091022875 Microtubule Proteins 0.000 description 1
• 241001024304 Mino Species 0.000 description 1
• 101100521345 Mus musculus Prop1 gene Proteins 0.000 description 1
• 101100366940 Mus musculus Stom gene Proteins 0.000 description 1
• 208000014767 Myeloproliferative disease Diseases 0.000 description 1
• JBBGBYPGZPWZBG-UHFFFAOYSA-N N-[3-[3-(1-piperidinylsulfonyl)anilino]-2-quinoxalinyl]benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC(C=1)=CC=CC=1S(=O)(=O)N1CCCCC1 JBBGBYPGZPWZBG-UHFFFAOYSA-N 0.000 description 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
• PAMIQIKDUOTOBW-UHFFFAOYSA-N N-methylcyclohexylamine Natural products CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
• MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
• 206010029260 Neuroblastoma Diseases 0.000 description 1
• 201000004404 Neurofibroma Diseases 0.000 description 1
• 208000005890 Neuroma Diseases 0.000 description 1
• 201000010133 Oligodendroglioma Diseases 0.000 description 1
• 102000038030 PI3Ks Human genes 0.000 description 1
• 108091007960 PI3Ks Proteins 0.000 description 1
• WSLBJQQQZZTFBA-MLUQOLBVSA-N PIP[4'](17:0/20:4(5Z,8Z,11Z,14Z)) Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(O)(=O)OC1C(O)C(O)C(OP(O)(O)=O)[C@@H](O)C1O WSLBJQQQZZTFBA-MLUQOLBVSA-N 0.000 description 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
• PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
• 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
• 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 208000007641 Pinealoma Diseases 0.000 description 1
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
• 108700017836 Prophet of Pit-1 Proteins 0.000 description 1
• 102000001253 Protein Kinase Human genes 0.000 description 1
• 101100425901 Rattus norvegicus Tpm1 gene Proteins 0.000 description 1
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
• 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
• 201000000582 Retinoblastoma Diseases 0.000 description 1
• 201000010208 Seminoma Diseases 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 101150098159 TSHR gene Proteins 0.000 description 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
• 206010043276 Teratoma Diseases 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
• 206010048214 Xanthoma Diseases 0.000 description 1
• 206010048215 Xanthomatosis Diseases 0.000 description 1
• LUBJCRLGQSPQNN-UHFFFAOYSA-N Z-phenylurea Natural products NC(=O)NC1=CC=CC=C1 LUBJCRLGQSPQNN-UHFFFAOYSA-N 0.000 description 1
• ZUSWDTWYONAOPH-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]hydrazine;hydrochloride Chemical group [Cl-].[NH3+]NC1=CC=CC=C1C(F)(F)F ZUSWDTWYONAOPH-UHFFFAOYSA-N 0.000 description 1
• RTQLGGYCJBBNQX-UHFFFAOYSA-N [4-[[3-[(4-acetamidophenyl)sulfonylamino]quinoxalin-2-yl]amino]phenyl] thiocyanate Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC1=CC=C(SC#N)C=C1 RTQLGGYCJBBNQX-UHFFFAOYSA-N 0.000 description 1
• ATNQJIZWZJGBST-UHFFFAOYSA-N [4-[[4-(3,4-dichloroanilino)-6-methoxyquinazolin-7-yl]oxymethyl]-1,3-thiazol-2-yl]methanol Chemical compound N1=CN=C2C=C(OCC=3N=C(CO)SC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1 ATNQJIZWZJGBST-UHFFFAOYSA-N 0.000 description 1
• SROSEDFOBYVYCH-UHFFFAOYSA-N [4-[[4-(3,4-dichloroanilino)-6-methoxyquinazolin-7-yl]oxymethyl]-1,3-thiazol-2-yl]methyl benzoate Chemical compound N1=CN=C2C=C(OCC=3N=C(COC(=O)C=4C=CC=CC=4)SC=3)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1 SROSEDFOBYVYCH-UHFFFAOYSA-N 0.000 description 1
• GYCFKAULNPNOKL-UHFFFAOYSA-N [6-(2-benzyl-1-hydroxy-3-oxoisoindol-1-yl)-1H-benzimidazol-2-yl] carbamate Chemical compound NC(=O)OC1=NC2=CC(=CC=C2N1)C1(O)N(CC2=CC=CC=C2)C(=O)C2=CC=CC=C12 GYCFKAULNPNOKL-UHFFFAOYSA-N 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 239000008186 active pharmaceutical agent Substances 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 125000004442 acylamino group Chemical group 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 208000002718 adenomatoid tumor Diseases 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 210000004100 adrenal gland Anatomy 0.000 description 1
• 206010064930 age-related macular degeneration Diseases 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 125000005090 alkenylcarbonyl group Chemical group 0.000 description 1
• 125000005093 alkyl carbonyl alkyl group Chemical group 0.000 description 1
• 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
• 125000005907 alkyl ester group Chemical group 0.000 description 1
• 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
• 125000000304 alkynyl group Chemical group 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 229960003437 aminoglutethimide Drugs 0.000 description 1
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
• XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
• 229960001220 amsacrine Drugs 0.000 description 1
• 229960002932 anastrozole Drugs 0.000 description 1
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
• 230000033115 angiogenesis Effects 0.000 description 1
• 239000003242 anti bacterial agent Substances 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000259 anti-tumor effect Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
• 229940120638 avastin Drugs 0.000 description 1
• 229960003005 axitinib Drugs 0.000 description 1
• RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
• LKYLLQLIEXZSBF-UHFFFAOYSA-N azetidine-3,3-dicarboxamide Chemical compound NC(=O)C1(C(N)=O)CNC1 LKYLLQLIEXZSBF-UHFFFAOYSA-N 0.000 description 1
• HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
• PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
• 150000008107 benzenesulfonic acids Chemical class 0.000 description 1
• 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
• LJTADZDNDVBKOW-UHFFFAOYSA-N benzyl 2-[2-(ethoxycarbonylamino)-1,3-benzoxazole-5-carbonyl]benzoate Chemical compound C=1C=C2OC(NC(=O)OCC)=NC2=CC=1C(=O)C1=CC=CC=C1C(=O)OCC1=CC=CC=C1 LJTADZDNDVBKOW-UHFFFAOYSA-N 0.000 description 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
• MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
• RSDOASZYYCOXIB-UHFFFAOYSA-N beta-alaninamide Chemical compound NCCC(N)=O RSDOASZYYCOXIB-UHFFFAOYSA-N 0.000 description 1
• 229940000635 beta-alanine Drugs 0.000 description 1
• 229960000397 bevacizumab Drugs 0.000 description 1
• 230000031018 biological processes and functions Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 201000003149 breast fibroadenoma Diseases 0.000 description 1
• 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
• 201000002143 bronchus adenoma Diseases 0.000 description 1
• MAYUYFCAPVDYBQ-UHFFFAOYSA-N butoxymethylbenzene Chemical compound CCCCOCC1=CC=CC=C1 MAYUYFCAPVDYBQ-UHFFFAOYSA-N 0.000 description 1
• BCCHDJPOFRDWIW-UHFFFAOYSA-N butyl 4-[[3-[(4-chlorophenyl)sulfonylamino]-7-methylquinoxalin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCCCC)=CC=C1NC1=NC2=CC(C)=CC=C2N=C1NS(=O)(=O)C1=CC=C(Cl)C=C1 BCCHDJPOFRDWIW-UHFFFAOYSA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
• 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
• 229940127093 camptothecin Drugs 0.000 description 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
• 229960004117 capecitabine Drugs 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
• 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
• 229960005243 carmustine Drugs 0.000 description 1
• 239000003729 cation exchange resin Substances 0.000 description 1
• 229940023913 cation exchange resins Drugs 0.000 description 1
• 230000034196 cell chemotaxis Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000010261 cell growth Effects 0.000 description 1
• 230000004709 cell invasion Effects 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000004663 cell proliferation Effects 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 208000019065 cervical carcinoma Diseases 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 229960005395 cetuximab Drugs 0.000 description 1
• 229940044683 chemotherapy drug Drugs 0.000 description 1
• 229960004630 chlorambucil Drugs 0.000 description 1
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
• MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical class ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• 125000000068 chlorophenyl group Chemical group 0.000 description 1
• 208000006990 cholangiocarcinoma Diseases 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
• 229960004106 citric acid Drugs 0.000 description 1
• 229960002436 cladribine Drugs 0.000 description 1
• 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
• 238000011284 combination treatment Methods 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 239000012059 conventional drug carrier Substances 0.000 description 1
• 239000002826 coolant Substances 0.000 description 1
• GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
• 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
• PMSVVUSIPKHUMT-UHFFFAOYSA-N cyanopyrazine Chemical compound N#CC1=CN=CC=N1 PMSVVUSIPKHUMT-UHFFFAOYSA-N 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 229960004397 cyclophosphamide Drugs 0.000 description 1
• JMYVMOUINOAAPA-UHFFFAOYSA-N cyclopropanecarbaldehyde Chemical compound O=CC1CC1 JMYVMOUINOAAPA-UHFFFAOYSA-N 0.000 description 1
• 229960000684 cytarabine Drugs 0.000 description 1
• 210000004292 cytoskeleton Anatomy 0.000 description 1
• 229960002448 dasatinib Drugs 0.000 description 1
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
• 229960003957 dexamethasone Drugs 0.000 description 1
• 125000004188 dichlorophenyl group Chemical group 0.000 description 1
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
• 125000004212 difluorophenyl group Chemical group 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
• 229960003668 docetaxel Drugs 0.000 description 1
• 239000002552 dosage form Substances 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 239000003937 drug carrier Substances 0.000 description 1
• 229940088679 drug related substance Drugs 0.000 description 1
• 238000001456 electron microprobe Auger spectroscopy Methods 0.000 description 1
• 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 229940116977 epidermal growth factor Drugs 0.000 description 1
• 229940082789 erbitux Drugs 0.000 description 1
• 210000003238 esophagus Anatomy 0.000 description 1
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
• BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
• MWZNSSPJQLLDKM-UHFFFAOYSA-N ethyl 2-[[3-[(2-methylphenyl)sulfonylamino]quinoxalin-2-yl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate Chemical compound S1C=2CCCCC=2C(C(=O)OCC)=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1C MWZNSSPJQLLDKM-UHFFFAOYSA-N 0.000 description 1
• JZSOIQHOQDFQOL-UHFFFAOYSA-N ethyl 2-[[3-[(2-methylphenyl)sulfonylamino]quinoxalin-2-yl]amino]-5,6-dihydro-4h-cyclopenta[b]thiophene-3-carboxylate Chemical compound S1C=2CCCC=2C(C(=O)OCC)=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1C JZSOIQHOQDFQOL-UHFFFAOYSA-N 0.000 description 1
• NXFUMPUWQYATNX-UHFFFAOYSA-N ethyl 2-[[3-[(3-nitrophenyl)sulfonylamino]quinoxalin-2-yl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate Chemical compound S1C=2CCCCC=2C(C(=O)OCC)=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 NXFUMPUWQYATNX-UHFFFAOYSA-N 0.000 description 1
• HUVQAVOPDYAFMX-UHFFFAOYSA-N ethyl 2-[[3-[(3-nitrophenyl)sulfonylamino]quinoxalin-2-yl]amino]-5,6-dihydro-4h-cyclopenta[b]thiophene-3-carboxylate Chemical compound S1C=2CCCC=2C(C(=O)OCC)=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC([N+]([O-])=O)=C1 HUVQAVOPDYAFMX-UHFFFAOYSA-N 0.000 description 1
• QMPBMQSXVKRHDB-UHFFFAOYSA-N ethyl 2-[[3-[(4-acetamido-3,5-dibromophenyl)sulfonylamino]quinoxalin-2-yl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate Chemical compound S1C=2CCCCC=2C(C(=O)OCC)=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC(Br)=C(NC(C)=O)C(Br)=C1 QMPBMQSXVKRHDB-UHFFFAOYSA-N 0.000 description 1
• NLTCXLHJESQGDK-UHFFFAOYSA-N ethyl 2-[[3-[(4-acetamidophenyl)sulfonylamino]quinoxalin-2-yl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate Chemical compound S1C=2CCCCC=2C(C(=O)OCC)=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(NC(C)=O)C=C1 NLTCXLHJESQGDK-UHFFFAOYSA-N 0.000 description 1
• HBPGBQPNEXGNOU-UHFFFAOYSA-N ethyl 2-[[3-[(4-acetamidophenyl)sulfonylamino]quinoxalin-2-yl]amino]-6-phenyl-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate Chemical compound S1C=2CC(C=3C=CC=CC=3)CCC=2C(C(=O)OCC)=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(NC(C)=O)C=C1 HBPGBQPNEXGNOU-UHFFFAOYSA-N 0.000 description 1
• VBFXJCSZOKMKMR-UHFFFAOYSA-N ethyl 6-methyl-2-[[3-[(2-methylphenyl)sulfonylamino]quinoxalin-2-yl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate Chemical compound S1C=2CC(C)CCC=2C(C(=O)OCC)=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=CC=C1C VBFXJCSZOKMKMR-UHFFFAOYSA-N 0.000 description 1
• FBTIJAAXOZSZLP-UHFFFAOYSA-N ethyl 6-methyl-2-[[3-[(4-methylphenyl)sulfonylamino]quinoxalin-2-yl]amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxylate Chemical compound S1C=2CC(C)CCC=2C(C(=O)OCC)=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(C)C=C1 FBTIJAAXOZSZLP-UHFFFAOYSA-N 0.000 description 1
• 229940093470 ethylene Drugs 0.000 description 1
• 229940012017 ethylenediamine Drugs 0.000 description 1
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
• 229960005420 etoposide Drugs 0.000 description 1
• LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
• 229960000752 etoposide phosphate Drugs 0.000 description 1
• ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 1
• 229950009429 exatecan Drugs 0.000 description 1
• 229960000255 exemestane Drugs 0.000 description 1
• 230000001747 exhibiting effect Effects 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
• 229960004039 finasteride Drugs 0.000 description 1
• 229960000390 fludarabine Drugs 0.000 description 1
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
• 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
• 229960002949 fluorouracil Drugs 0.000 description 1
• 210000004186 follicle cell Anatomy 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 229960004421 formestane Drugs 0.000 description 1
• OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
• 229960004783 fotemustine Drugs 0.000 description 1
• YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
• 239000001530 fumaric acid Substances 0.000 description 1
• 238000004817 gas chromatography Methods 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
• 201000000052 gastrinoma Diseases 0.000 description 1
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
• 229960005277 gemcitabine Drugs 0.000 description 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
• 229960000578 gemtuzumab Drugs 0.000 description 1
• 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
• 230000002068 genetic effect Effects 0.000 description 1
• 229940084910 gliadel Drugs 0.000 description 1
• 229960002442 glucosamine Drugs 0.000 description 1
• 125000000262 haloalkenyl group Chemical group 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 208000006359 hepatoblastoma Diseases 0.000 description 1
• 201000002735 hepatocellular adenoma Diseases 0.000 description 1
• DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
• 229940022353 herceptin Drugs 0.000 description 1
• IWCAQTQMDRGMPI-UHFFFAOYSA-N hexane-3,4-diamine Chemical compound CCC(N)C(N)CC IWCAQTQMDRGMPI-UHFFFAOYSA-N 0.000 description 1
• XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
• 229960001101 ifosfamide Drugs 0.000 description 1
• 125000001841 imino group Chemical group [H]N=* 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 201000004933 in situ carcinoma Diseases 0.000 description 1
• QNLOWBMKUIXCOW-UHFFFAOYSA-N indol-2-one Chemical compound C1=CC=CC2=NC(=O)C=C21 QNLOWBMKUIXCOW-UHFFFAOYSA-N 0.000 description 1
• 125000004531 indol-5-yl group Chemical group [H]N1C([H])=C([H])C2=C([H])C(*)=C([H])C([H])=C12 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 229940125396 insulin Drugs 0.000 description 1
• 210000002570 interstitial cell Anatomy 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
• 229960004768 irinotecan Drugs 0.000 description 1
• VFQXVTODMYMSMJ-UHFFFAOYSA-N isonicotinamide Chemical compound NC(=O)C1=CC=NC=C1 VFQXVTODMYMSMJ-UHFFFAOYSA-N 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 210000003734 kidney Anatomy 0.000 description 1
• 208000022013 kidney Wilms tumor Diseases 0.000 description 1
• 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 description 1
• 210000002429 large intestine Anatomy 0.000 description 1
• 229960003881 letrozole Drugs 0.000 description 1
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
• 208000032839 leukemia Diseases 0.000 description 1
• 206010024627 liposarcoma Diseases 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 239000008297 liquid dosage form Substances 0.000 description 1
• 210000004185 liver Anatomy 0.000 description 1
• 229960002247 lomustine Drugs 0.000 description 1
• RVFGKBWWUQOIOU-NDEPHWFRSA-N lurtotecan Chemical compound O=C([C@]1(O)CC)OCC(C(N2CC3=4)=O)=C1C=C2C3=NC1=CC=2OCCOC=2C=C1C=4CN1CCN(C)CC1 RVFGKBWWUQOIOU-NDEPHWFRSA-N 0.000 description 1
• 229950002654 lurtotecan Drugs 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 229920002521 macromolecule Polymers 0.000 description 1
• 208000002780 macular degeneration Diseases 0.000 description 1
• 159000000003 magnesium salts Chemical class 0.000 description 1
• WRIRWRKPLXCTFD-UHFFFAOYSA-N malonamide Chemical compound NC(=O)CC(N)=O WRIRWRKPLXCTFD-UHFFFAOYSA-N 0.000 description 1
• 238000004519 manufacturing process Methods 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
• 229960001924 melphalan Drugs 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 206010027191 meningioma Diseases 0.000 description 1
• GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
• 229960001428 mercaptopurine Drugs 0.000 description 1
• 208000030159 metabolic disease Diseases 0.000 description 1
• 230000004060 metabolic process Effects 0.000 description 1
• 229910021645 metal ion Inorganic materials 0.000 description 1
• 229940098779 methanesulfonic acid Drugs 0.000 description 1
• 229960000485 methotrexate Drugs 0.000 description 1
• IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
• LCTFMYBJTAJFBD-UHFFFAOYSA-N methyl n-[6-(2-benzyl-1-ethoxy-3-oxoisoindol-1-yl)-1h-benzimidazol-2-yl]carbamate Chemical compound O=C1C2=CC=CC=C2C(OCC)(C=2C=C3N=C(NC(=O)OC)NC3=CC=2)N1CC1=CC=CC=C1 LCTFMYBJTAJFBD-UHFFFAOYSA-N 0.000 description 1
• MMNNTJYFHUDSKL-UHFFFAOYSA-N methyl n-[6-[2-(5-chloro-2-methylphenyl)-1-hydroxy-3-oxoisoindol-1-yl]-1h-benzimidazol-2-yl]carbamate Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(C1=CC=CC=C1C1=O)(O)N1C1=CC(Cl)=CC=C1C MMNNTJYFHUDSKL-UHFFFAOYSA-N 0.000 description 1
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 1
• 230000002906 microbiologic effect Effects 0.000 description 1
• 210000004688 microtubule Anatomy 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 239000003607 modifier Substances 0.000 description 1
• STUHQDIOZQUPGP-UHFFFAOYSA-N morpholin-4-ium-4-carboxylate Chemical compound OC(=O)N1CCOCC1 STUHQDIOZQUPGP-UHFFFAOYSA-N 0.000 description 1
• 125000002912 morpholin-4-ylsulfonyl group Chemical group O1C([H])([H])C([H])([H])N(S(=O)(=O)[*])C([H])([H])C1([H])[H] 0.000 description 1
• ZKWFSTHEYLJLEL-UHFFFAOYSA-N morpholine-4-carboxamide Chemical compound NC(=O)N1CCOCC1 ZKWFSTHEYLJLEL-UHFFFAOYSA-N 0.000 description 1
• WCUWHUUPGXCMMQ-UHFFFAOYSA-N morpholine-4-carboximidamide Chemical compound NC(=N)N1CCOCC1 WCUWHUUPGXCMMQ-UHFFFAOYSA-N 0.000 description 1
• 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 208000009091 myxoma Diseases 0.000 description 1
• XWXWVDUQFFBTMA-UHFFFAOYSA-N n-(cyclopropanecarbonyl)azetidine-3-carboxamide Chemical compound C1CC1C(=O)NC(=O)C1CNC1 XWXWVDUQFFBTMA-UHFFFAOYSA-N 0.000 description 1
• PEAFOUHADOOIMF-UHFFFAOYSA-N n-[3-(2,5-dimethoxyanilino)-7-methylquinoxalin-2-yl]benzenesulfonamide Chemical compound COC1=CC=C(OC)C(NC=2C(=NC3=CC(C)=CC=C3N=2)NS(=O)(=O)C=2C=CC=CC=2)=C1 PEAFOUHADOOIMF-UHFFFAOYSA-N 0.000 description 1
• LDGVJARGUDCVOA-UHFFFAOYSA-N n-[3-(2-ethoxyanilino)quinoxalin-2-yl]-4-methylbenzenesulfonamide Chemical compound CCOC1=CC=CC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(C)C=C1 LDGVJARGUDCVOA-UHFFFAOYSA-N 0.000 description 1
• PERPCKGKQXEVKY-UHFFFAOYSA-N n-[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 PERPCKGKQXEVKY-UHFFFAOYSA-N 0.000 description 1
• BWLPXMKWMRGOKV-UHFFFAOYSA-N n-[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]-4-methylbenzenesulfonamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC(C)=CC=2)=C1 BWLPXMKWMRGOKV-UHFFFAOYSA-N 0.000 description 1
• CBMXAFMMKWIIFV-UHFFFAOYSA-N n-[3-(3-fluoro-5-methoxyanilino)quinoxalin-2-yl]-3-nitrobenzenesulfonamide Chemical compound COC1=CC(F)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(C=CC=2)[N+]([O-])=O)=C1 CBMXAFMMKWIIFV-UHFFFAOYSA-N 0.000 description 1
• FKJFEGWXADUNOM-UHFFFAOYSA-N n-[3-(3-methoxyanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound COC1=CC=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC=CC=2)=C1 FKJFEGWXADUNOM-UHFFFAOYSA-N 0.000 description 1
• DVBCTPSEVZPJQD-UHFFFAOYSA-N n-[3-(4-chloro-3-methoxyanilino)quinoxalin-2-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=CC=CC=2)=C1 DVBCTPSEVZPJQD-UHFFFAOYSA-N 0.000 description 1
• DBXGCOVTUVEWFR-UHFFFAOYSA-N n-[3-(4-ethoxyanilino)-6-methylquinoxalin-2-yl]-4-methylbenzenesulfonamide Chemical compound C1=CC(OCC)=CC=C1NC1=NC2=CC(C)=CC=C2N=C1NS(=O)(=O)C1=CC=C(C)C=C1 DBXGCOVTUVEWFR-UHFFFAOYSA-N 0.000 description 1
• WYNCOSFPFNDWAF-UHFFFAOYSA-N n-[3-(4-ethoxyanilino)quinoxalin-2-yl]-4-methylbenzenesulfonamide Chemical compound C1=CC(OCC)=CC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(C)C=C1 WYNCOSFPFNDWAF-UHFFFAOYSA-N 0.000 description 1
• SKLSHCWBXLGPEZ-UHFFFAOYSA-N n-[3-(naphthalen-2-ylamino)quinoxalin-2-yl]benzenesulfonamide Chemical compound N=1C2=CC=CC=C2N=C(NC=2C=C3C=CC=CC3=CC=2)C=1NS(=O)(=O)C1=CC=CC=C1 SKLSHCWBXLGPEZ-UHFFFAOYSA-N 0.000 description 1
• ZTTONCWDPOKYHY-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-1,3-benzodioxole-5-carboxamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C=C4OCOC4=CC=3)C=CC=2)=C1 ZTTONCWDPOKYHY-UHFFFAOYSA-N 0.000 description 1
• GZEPXUHUXXQUQT-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-1-hydroxycyclopropane-1-carboxamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C3(O)CC3)C=CC=2)=C1 GZEPXUHUXXQUQT-UHFFFAOYSA-N 0.000 description 1
• PXYIKFUIKXXXBQ-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-1-methylcyclopropane-1-carboxamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C3(C)CC3)C=CC=2)=C1 PXYIKFUIKXXXBQ-UHFFFAOYSA-N 0.000 description 1
• XFEVBZGOTOTHMX-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2,2-dimethylpropanamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)(C)C)C=CC=2)=C1 XFEVBZGOTOTHMX-UHFFFAOYSA-N 0.000 description 1
• CTVVPTPFZZYEDE-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-fluoro-5-methylbenzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C(=CC=C(C)C=3)F)C=CC=2)=C1 CTVVPTPFZZYEDE-UHFFFAOYSA-N 0.000 description 1
• XJMQMOFGCVWMJN-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpentanamide Chemical compound CCCC(C)C(=O)NC1=CC=CC(S(=O)(=O)NC=2C(=NC3=CC=CC=C3N=2)NC=2C=C(OC)C=C(OC)C=2)=C1 XJMQMOFGCVWMJN-UHFFFAOYSA-N 0.000 description 1
• MYVNJTNJUKGQGS-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C(C)C)C=CC=2)=C1 MYVNJTNJUKGQGS-UHFFFAOYSA-N 0.000 description 1
• JMAKCKLXOBBGLH-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-pyridin-3-ylacetamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)CC=3C=NC=CC=3)C=CC=2)=C1 JMAKCKLXOBBGLH-UHFFFAOYSA-N 0.000 description 1
• FWWSVNCKBXMXIU-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-fluoro-2-methylbenzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C(=C(F)C=CC=3)C)C=CC=2)=C1 FWWSVNCKBXMXIU-UHFFFAOYSA-N 0.000 description 1
• QVURLIFUNKQFGH-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-fluoro-4-methylbenzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C=C(F)C(C)=CC=3)C=CC=2)=C1 QVURLIFUNKQFGH-UHFFFAOYSA-N 0.000 description 1
• UTXXRURKYSZMPA-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-methylpyridine-2-carboxamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C(=CC=CN=3)C)C=CC=2)=C1 UTXXRURKYSZMPA-UHFFFAOYSA-N 0.000 description 1
• WZAYDPPDMIUEPF-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-3-oxocyclopentane-1-carboxamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C3CC(=O)CC3)C=CC=2)=C1 WZAYDPPDMIUEPF-UHFFFAOYSA-N 0.000 description 1
• CSZOXUNUHYHYGT-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-4-fluorobenzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C=CC(F)=CC=3)C=CC=2)=C1 CSZOXUNUHYHYGT-UHFFFAOYSA-N 0.000 description 1
• OWMGEQXQRVCEQS-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-4-methylbenzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C=CC(C)=CC=3)C=CC=2)=C1 OWMGEQXQRVCEQS-UHFFFAOYSA-N 0.000 description 1
• VDWFEVUZVHGJRL-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-5-fluoro-2-methylbenzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C(=CC=C(F)C=3)C)C=CC=2)=C1 VDWFEVUZVHGJRL-UHFFFAOYSA-N 0.000 description 1
• BZTJELQROTYXKP-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-5-methyl-1,2-oxazole-3-carboxamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C3=NOC(C)=C3)C=CC=2)=C1 BZTJELQROTYXKP-UHFFFAOYSA-N 0.000 description 1
• HQTOOQVCMOVKNA-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]acetamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(C)=O)C=CC=2)=C1 HQTOOQVCMOVKNA-UHFFFAOYSA-N 0.000 description 1
• KIBGXNJREXXTNO-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]benzamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C=3C=CC=CC=3)C=CC=2)=C1 KIBGXNJREXXTNO-UHFFFAOYSA-N 0.000 description 1
• QSMPWECTQKIIFQ-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]cyclobutanecarboxamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C3CCC3)C=CC=2)=C1 QSMPWECTQKIIFQ-UHFFFAOYSA-N 0.000 description 1
• JQGPBRSLUVOBRP-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]oxolane-3-carboxamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C3COCC3)C=CC=2)=C1 JQGPBRSLUVOBRP-UHFFFAOYSA-N 0.000 description 1
• LKNJWFRTLLWKLT-UHFFFAOYSA-N n-[3-[[3-(3,5-dimethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]thiophene-3-carboxamide Chemical compound COC1=CC(OC)=CC(NC=2C(=NC3=CC=CC=C3N=2)NS(=O)(=O)C=2C=C(NC(=O)C3=CSC=C3)C=CC=2)=C1 LKNJWFRTLLWKLT-UHFFFAOYSA-N 0.000 description 1
• ITFRDFBCXXLZIJ-UHFFFAOYSA-N n-[4-[[3-(2-bromo-4-methylanilino)quinoxalin-2-yl]sulfamoyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1NC1=CC=C(C)C=C1Br ITFRDFBCXXLZIJ-UHFFFAOYSA-N 0.000 description 1
• DHSZNDYFHBIMEZ-UHFFFAOYSA-N n-[4-[[3-(4-ethoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]acetamide Chemical compound C1=CC(OCC)=CC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(NC(C)=O)C=C1 DHSZNDYFHBIMEZ-UHFFFAOYSA-N 0.000 description 1
• FYKLPRKNJSPGON-UHFFFAOYSA-O n-[4-[[3-(4-methylpyridin-1-ium-1-yl)quinoxalin-2-yl]sulfamoyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1S(=O)(=O)NC1=NC2=CC=CC=C2N=C1[N+]1=CC=C(C)C=C1 FYKLPRKNJSPGON-UHFFFAOYSA-O 0.000 description 1
• GGDRMKGZRIVKSM-UHFFFAOYSA-N n-[4-[[3-[(4-chlorophenyl)sulfonylamino]quinoxalin-2-yl]amino]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1NC1=NC2=CC=CC=C2N=C1NS(=O)(=O)C1=CC=C(Cl)C=C1 GGDRMKGZRIVKSM-UHFFFAOYSA-N 0.000 description 1
• BNSJFNNZNDNXBN-UHFFFAOYSA-N n-benzylazetidine-3-carboxamide Chemical compound C1NCC1C(=O)NCC1=CC=CC=C1 BNSJFNNZNDNXBN-UHFFFAOYSA-N 0.000 description 1
• ARFKGONNPZNFOM-UHFFFAOYSA-N n-methoxybenzenesulfonamide Chemical compound CONS(=O)(=O)C1=CC=CC=C1 ARFKGONNPZNFOM-UHFFFAOYSA-N 0.000 description 1
• 239000002105 nanoparticle Substances 0.000 description 1
• ZFIFHAKCBWOSRN-UHFFFAOYSA-N naphthalene-1-sulfonamide Chemical compound C1=CC=C2C(S(=O)(=O)N)=CC=CC2=C1 ZFIFHAKCBWOSRN-UHFFFAOYSA-N 0.000 description 1
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
• 229960001346 nilotinib Drugs 0.000 description 1
• BVOCPVIXARZNQN-UHFFFAOYSA-N nipecotamide Chemical compound NC(=O)C1CCCNC1 BVOCPVIXARZNQN-UHFFFAOYSA-N 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 125000006501 nitrophenyl group Chemical group 0.000 description 1
• 239000012457 nonaqueous media Substances 0.000 description 1
• 230000035764 nutrition Effects 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• OIPZNTLJVJGRCI-UHFFFAOYSA-M octadecanoyloxyaluminum;dihydrate Chemical compound O.O.CCCCCCCCCCCCCCCCCC(=O)O[Al] OIPZNTLJVJGRCI-UHFFFAOYSA-M 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 208000003388 osteoid osteoma Diseases 0.000 description 1
• 208000008798 osteoma Diseases 0.000 description 1
• 229940127084 other anti-cancer agent Drugs 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• 229960001756 oxaliplatin Drugs 0.000 description 1
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
• 230000003647 oxidation Effects 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000006179 pH buffering agent Substances 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 229960001972 panitumumab Drugs 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 229960000639 pazopanib Drugs 0.000 description 1
• CUIHSIWYWATEQL-UHFFFAOYSA-N pazopanib Chemical compound C1=CC2=C(C)N(C)N=C2C=C1N(C)C(N=1)=CC=NC=1NC1=CC=C(C)C(S(N)(=O)=O)=C1 CUIHSIWYWATEQL-UHFFFAOYSA-N 0.000 description 1
• 229950006299 pelitinib Drugs 0.000 description 1
• WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
• 229960005079 pemetrexed Drugs 0.000 description 1
• 239000008177 pharmaceutical agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 229960003742 phenol Drugs 0.000 description 1
• 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
• 208000024724 pineal body neoplasm Diseases 0.000 description 1
• 201000004123 pineal gland cancer Diseases 0.000 description 1
• RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
• BRYCUMKDWMEGMK-UHFFFAOYSA-N piperazine-2-carboxamide Chemical compound NC(=O)C1CNCCN1 BRYCUMKDWMEGMK-UHFFFAOYSA-N 0.000 description 1
• 239000002574 poison Substances 0.000 description 1
• 231100000614 poison Toxicity 0.000 description 1
• 229920000768 polyamine Polymers 0.000 description 1
• 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 150000003140 primary amides Chemical class 0.000 description 1
• 150000003141 primary amines Chemical class 0.000 description 1
• 230000002062 proliferating effect Effects 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 235000019260 propionic acid Nutrition 0.000 description 1
• XVXJMMNMOBZILJ-UHFFFAOYSA-N propyl 4-[[3-[(4-chlorophenyl)sulfonylamino]-7-methylquinoxalin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCCC)=CC=C1NC1=NC2=CC(C)=CC=C2N=C1NS(=O)(=O)C1=CC=C(Cl)C=C1 XVXJMMNMOBZILJ-UHFFFAOYSA-N 0.000 description 1
• AOHJOMMDDJHIJH-UHFFFAOYSA-N propylenediamine Chemical compound CC(N)CN AOHJOMMDDJHIJH-UHFFFAOYSA-N 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 108060006633 protein kinase Proteins 0.000 description 1
• 239000003909 protein kinase inhibitor Substances 0.000 description 1
• 102000004169 proteins and genes Human genes 0.000 description 1
• 125000004289 pyrazol-3-yl group Chemical group [H]N1N=C(*)C([H])=C1[H] 0.000 description 1
• 125000004528 pyrimidin-5-yl group Chemical group N1=CN=CC(=C1)* 0.000 description 1
• 238000012797 qualification Methods 0.000 description 1
• 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
• 230000009467 reduction Effects 0.000 description 1
• 238000006722 reduction reaction Methods 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 230000008521 reorganization Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 238000012827 research and development Methods 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229960004641 rituximab Drugs 0.000 description 1
• 150000003870 salicylic acids Chemical class 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 229950003647 semaxanib Drugs 0.000 description 1
• WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 238000009097 single-agent therapy Methods 0.000 description 1
• 210000003625 skull Anatomy 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 239000002195 soluble material Substances 0.000 description 1
• 239000000243 solution Substances 0.000 description 1
• 239000004334 sorbic acid Substances 0.000 description 1
• 235000010199 sorbic acid Nutrition 0.000 description 1
• 229940075582 sorbic acid Drugs 0.000 description 1
• 229940035044 sorbitan monolaurate Drugs 0.000 description 1
• 238000010183 spectrum analysis Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
• 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
• 150000003456 sulfonamides Chemical class 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 230000002195 synergetic effect Effects 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 229960001603 tamoxifen Drugs 0.000 description 1
• 229940120982 tarceva Drugs 0.000 description 1
• 229960004964 temozolomide Drugs 0.000 description 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
• 229960001278 teniposide Drugs 0.000 description 1
• 208000001608 teratocarcinoma Diseases 0.000 description 1
• MFHPFBVKYHTFKA-UHFFFAOYSA-N tert-butyl 2-[2-[4-(3,4-dichloroanilino)-6-methoxyquinazolin-7-yl]oxyethyl]-5,5-dimethylmorpholine-4-carboxylate Chemical compound N1=CN=C2C=C(OCCC3OCC(C)(C)N(C(=O)OC(C)(C)C)C3)C(OC)=CC2=C1NC1=CC=C(Cl)C(Cl)=C1 MFHPFBVKYHTFKA-UHFFFAOYSA-N 0.000 description 1
• LGYJTWAGMFCBDR-UHFFFAOYSA-N tert-butyl 4-[[4-[3-chloro-5-[[3-(4-fluoroanilino)-3-oxopropanoyl]amino]pyridin-2-yl]oxy-6-methoxyquinolin-7-yl]oxymethyl]piperidine-1-carboxylate Chemical compound C1=CN=C2C=C(OCC3CCN(CC3)C(=O)OC(C)(C)C)C(OC)=CC2=C1OC(C(=C1)Cl)=NC=C1NC(=O)CC(=O)NC1=CC=C(F)C=C1 LGYJTWAGMFCBDR-UHFFFAOYSA-N 0.000 description 1
• 150000003512 tertiary amines Chemical class 0.000 description 1
• 238000012360 testing method Methods 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 230000001225 therapeutic effect Effects 0.000 description 1
• MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
• 229960003087 tioguanine Drugs 0.000 description 1
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
• 229960000303 topotecan Drugs 0.000 description 1
• 229960005267 tositumomab Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 206010044412 transitional cell carcinoma Diseases 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 229960000575 trastuzumab Drugs 0.000 description 1
• 229940117013 triethanolamine oleate Drugs 0.000 description 1
• 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
• 239000001226 triphosphate Substances 0.000 description 1
• 235000011178 triphosphate Nutrition 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 229960000281 trometamol Drugs 0.000 description 1
• 208000022271 tubular adenoma Diseases 0.000 description 1
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
• 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 229960001055 uracil mustard Drugs 0.000 description 1
• 210000003708 urethra Anatomy 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 210000001215 vagina Anatomy 0.000 description 1
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
• 229910052720 vanadium Inorganic materials 0.000 description 1
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
• 230000028973 vesicle-mediated transport Effects 0.000 description 1
• 208000009540 villous adenoma Diseases 0.000 description 1
• 229960003048 vinblastine Drugs 0.000 description 1
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
• 229960004528 vincristine Drugs 0.000 description 1
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
• UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
• 229960004355 vindesine Drugs 0.000 description 1
• NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
• 229960000922 vinflunine Drugs 0.000 description 1
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
• 229960002066 vinorelbine Drugs 0.000 description 1
• 210000003905 vulva Anatomy 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1